Ocrelizumab

From Wikipedia, the free encyclopedia

This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (July 2008)

Ocrelizumab^?
Therapeutic monoclonal antibody
Source	recombinant
Target	CD20
Identifiers
CAS number	637334-45-3
ATC code	?
PubChem	?
Chemical data
Formula	C₆₄₉₄H₉₉₇₈N₁₇₁₈O₂₀₁₄S₄₆
Mol. mass	148 kDa
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Ocrelizumab is a humanized anti CD20 monoclonal antibody. It targets mature B lymphocytes. As of May 2007 it is in clinical trials (phase III) for rheumatoid arthritis, multiple sclerosis and lupus erythematosus.^[1]

[edit] See also

rituximab, a chimeric CD20 agonist.
ofatumumab (HuMax-CD20) a fully-human CD20 agonist.

[edit] References

^ Note: information included in this article only found in table present in print version of article. K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields", Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., p. 36. Retrieved on 6 July 2008.

v • d • e

Immunomodulators – Immunosuppressants – Immunosuppressive drugs (L04)

Intracellular
(signal initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus

TNF-α inhibitor	Thalidomide

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab, Nerelimomab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-13 (Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab, Ziralimumab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

Polyclonal

Anti-thymocyte globulin · Anti-lymphocyte globulin

-cept (Fusion protein)

CTLA-4 (Abatacept, Belatacept) · Aflibercept · Alefacept · Rilonacept · TNF inhibitor (Etanercept)

Intracellular
(signal reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus

v • d • e Humanized monoclonal antibodies ("-zu-")

"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Claretuzumab tetraxetan, Clivatuzumab tetraxetan, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^†, Milatuzumab, Nimotuzumab, Pamtuzumab tetraxetan*, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab

"-lizu-" (immune system)	immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rintalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412 non-immunosuppressive:* Ibalizumab^†

"-bazu-" (bacterial)	Tefibazumab^†

"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab, Sonepcizumab, Tadocizumab

"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab, Stolanezumab*, Tanezumab

"-toxazu-" (toxin as target)	Urtoxazumab

"-vizu-" (viral infections)	Felvizumab, Motavizumab, Palivizumab, PRO 140^†

"-kinzu-" (interleukin as target)	Anrukinzumab, Drimakinzumab, Ginakinzumab, Vimakinzumab, Vontakinzumab

*Names under consideration by the USAN Council. ^†Undergoing clinical trials.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wikipedia.org/wiki/Ocrelizumab"

Categories: Monoclonal antibodies | Monoclonal antibody stubs

Hidden categories: Articles needing additional references from July 2008 | Drug pages needing formula fontification

Ocrelizumab

From Wikipedia, the free encyclopedia

[edit] See also

[edit] References

WANT TO ADVERTISE ON ALL OF OVER 11 MILLION SUBPAGES WE HAVE ON THIS SITE FOR UNDER $15? CLICK HERE!